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Abstract
Studies in animal models and humans suggest anti-inflammatory roles on the N-acylethanolamide (NAE)-peroxisome
proliferators activated receptor alpha (PPARa) system in inflammatory bowel diseases. However, the presence and function
of NAE-PPARa signaling system in the ulcerative colitis (UC) of humans remain unknown as well as its response to active
anti-inflammatory therapies such as 5-aminosalicylic acid (5-ASA) and glucocorticoids. Expression of PPARa receptor and
PPARa ligands-biosynthetic (NAPE-PLD) and -degrading (FAAH and NAAA) enzymes were analyzed in untreated active and
5-ASA/glucocorticoids/immunomodulators-treated quiescent UC patients compared to healthy human colonic tissue by RT-
PCR and immunohistochemical analyses. PPARa, NAAA, NAPE-PLD and FAAH showed differential distributions in the colonic
epithelium, lamina propria, smooth muscle and enteric plexus. Gene expression analysis indicated a decrease of PPARa,
PPARc and NAAA, and an increase of FAAH and iNOS in the active colitis mucosa. Immunohistochemical expression in active
colitis epithelium confirmed a PPARa decrease, but showed a sharp NAAA increase and a NAPE-PLD decrease, which were
partially restored to control levels after treatment. We also characterized the immune cells of the UC mucosa infiltrate. We
detected a decreased number of NAAA-positive and an increased number of FAAH-positive immune cells in active UC,
which were partially restored to control levels after treatment. NAE-PPARa signaling system is impaired during active UC
and 5-ASA/glucocorticoids treatment restored its normal expression. Since 5-ASA actions may work through PPARa and
glucocorticoids through NAE-producing/degrading enzymes, the use of PPARa agonists or FAAH/NAAA blockers that
increases endogenous PPARa ligands may yield similar therapeutics advantages.
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Introduction
Ulcerative colitis (UC) is a chronic relapsing inflammation of the
colonic tissue caused by the influence of complex genetic and
environmental interactions [1]. Different pro-inflammatory fac-
tors, including reactive oxygen and nitrogen metabolites, eicosa-
noids, platelet-activating factors and cytokines, are upregulated
and actively contribute to an exacerbated intestinal immune
response to otherwise innocuous stimuli [2,3]. For the manage-
ment of human UC, several drugs are currently used as 5-
aminosalicylic acid (5-ASA), glucocorticoids, anti-TNFa and
immunomodulators as thiopurines, which interfere with pro-
inflammatory cascades and effectively down-regulate the overstat-
ed inflammatory response [4–6]. Evidences suggested that the
anti-inflammatory effect of 5-ASA can be mediated by the
activation of peroxisome proliferator-activated receptors (PPARs),
such as PPARa and PPARc [7–11], which are highly expressed in
the intestinal and colonic mucosa by both epithelial cells and
macrophages [12–14]. UC patients seem to have reduced levels of
PPARc in their colonic epithelium and similar deficiencies were
observed in colitis mouse models, but only in macrophages of the
lamina propria [15,16]; confirming the beneficial effects of PPARc
agonists on the attenuation of colon inflammation [17,18]. Less
information is available on PPARa and b/d receptors.
Recent studies in experimental colitis suggested that PPARa
ligands also have anti-inflammatory properties, which was
enhanced after glucocorticoid treatment, but was weakened in
PPARa-null mice [19–23]. Moreover, 5-ASA is able to induce
PPARa expression and promote its translocation to the nucleus in
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Role of PPARa in Human Ulcerative Colitis
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37729an animal model of irradiation-induced intestinal inflammation
[11]. PPARa is specifically expressed in the more differentiated
colonic epithelial cells facing the intestinal lumen of the small
intestine and colon [12–14]. Thus, PPARa has been proposed to
participate in the intestinal epithelial barrier system; absence of
PPARa expression resulted in an increase of tight junction
permeability associated with apoptosis in an animal model of
experimental colitis [20]. PPARa signaling system is an anti-
inflammatory system composed of the PPARa receptor and its
endogenous ligands, the N-acylethanolamides oleoylethanolamide
(OEA) and palmitoylethanolamide (PEA). It also includes the
enzymes involved in their biosynthesis and release, such as N-acyl
phosphatidylethanolamide-specific phospholipase D (NAPE-PLD),
as well as mechanisms for cellular uptake and hydrolysis, such as
fatty acid amide hydrolase (FAAH) and N-acylethanolamide-
hydrolyzing acid amidase (NAAA) [24–26]. Increased PPARa
expression or enhanced PPARa ligand production can attenuate
inflammatory process observed in current animal models of
experimental colitis. For instance, treatment with FAAH antag-
onists or genetic ablation of FAAH protected against colitis
inflammation [27–29]. Thus, PPARa system is positioned to exert
a putative role in many of the points where homeostasis breaks in
UC, although the anti-inflammatory role of PPARa remains to be
determined in humans.
The aim of the present study is to analyze the expression and
distribution of components of the acylethanolamide-PPARa anti-
inflammatory system such as PPARa receptor and the enzymes
involved in endogenous ligand degradation (FAAH and NAAA)
and biosynthesis (NAPE-PLD) in the normal human colonic tissue
compared to untreated active UC at disease onset and after
achieving remission, according to clinical and endoscopic criteria,
and depending on treatment received (5-ASA, glucocorticoids
and/or immunomodulators).
Methods
Ethics statement
Biopsies and colonic resection samples used for the present
study were obtained after a written inform consent from all the
patients, as requested by the clinical guides of Hospital del Mar.
Research procedures were approved by the Hospital del Mar and
Hospital Carlos Haya Clinical Research and Ethics Committee
and were conducted according to the principles expressed in the
Declaration of Helsinki.
Subjects
We selected retrospectively 24 consecutive patients diagnosed
from January 2006 to December 2007 of a first flare of UC, with
extensive or left-side extension according to the Montreal
classification (E2 and E3) [30]. UC was defined by the criteria
of Lennard-Jones [31]. All patients had to achieve clinical and
endoscopic remission after medical treatment according to
Truelove-Witts index (,6 points) [32] and endoscopic Mayo
score (score=0) [33] during 12 months of diagnosis. We excluded
patients with distal UC according to Montreal classification (E1)
and patients without clinical and endoscopic remission criteria
after treatment. Thus, we obtained several endoscopic samples of
UC mucosa from each patient collected before any treatment
(active group), and after medical treatment and endoscopic
remission (quiescent group).
Colonic samples were retrieved from tissue bank of Pathology
Service at the Hospital del Mar. Data from each patients were
collected retrospectively from medical records including age, sex,
smoking habits and alcohol history, body mass index and
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37729extraintestinal manifestations, date of diagnosis, disease location
(Montreal classification), endoscopic lesions (Mayo clinic score)
and clinical score according Truelove and Witts index at onset,
and medical treatment received to induce remission after
diagnosis: 5-aminosalicilates (3 cases), glucocorticoids (15 cases),
and/or the immunomodulators cyclosporine A and azathioprine
(6 cases) (Table 1).
For the control group, we selected retrospectively 22 patients
who were pathohistologically given a definite diagnosis of
colorectal cancer and who had not received preoperative
radiotherapy or chemotherapy treatment and underwent colonic
resections for colorectal cancer. Several colonic resections were
obtained from each patient at least 10 cm from the tumour
(control group). We confirmed histopathologically the absence of
microscopic alterations (Table 2).
Colonic samples were frozen at 280uC for molecular analysis
(N=7–8) or fixated with 4% paraformadehyde in 0.1 M
phosphate buffered saline (PBS) by immersion and included in
paraffin until immunohistochemical analysis (N=22–24). The
analysis of the immunostaining patterns was carried out at
transmural planes of the normal and pathological colonic tissue
by comparing it with hematoxylin-eosin staining.
mRNA isolation and quantitative RT-PCR analysis
In order to evaluate the mRNA expression we collected
prospectively 7 colonic endoscopic biopsies from patients with a
first flare of active UC and 8 colonic resections, at least 10 cm
from the tumour, of patients with colorectal cancer (control
group). Colonic resections were divided into mucosa, containing
both epithelium and lamina propria, and submucosa layers,
containing smooth muscle and enteric plexi. Reverse transcript
reaction was carried out from 4 mg of mRNA using the
Transcriptor Reverse Transcriptase kit and random hexamer
primers (Transcriptor RT, Roche Diagnostic GmbH, Manheim,
Germany). Quantitative real-time reverse transcription polymer-
ase chain reaction (quantitative RT-PCR) was performed using a
CFX96TM Real-Time PCR Detection System (Bio-Rad Labora-
tories, Hercules, CA, USA), and the SYBR Green detection
format (FastStart Universal Master Kit, Roche, Mannheim,
Germany). Each reaction was run in duplicate and contained
5 ml of cDNA. Quantification was carried out with the classic
standard curve method run at the same time. We analyzed the
housekeeping genes SP1 transcription factor and bACTIN,
selecting the most suitable according to their homogeneity (Figure
S1). Absolute values from each sample were normalized with
regard to the housekeeping gene SP1. Primers for PCR reaction
were designed based on NCBI database sequences of human
reference mRNA (Table 3), checked for specificity with BLAST
software from NCBI website (http://blast.ncbi.nlm.nih.gov/Blast.
cgi) and synthesized by Invitrogen.
Western blotting
In order to evaluate the presence of PPARa, NAAA, NAPE-
PLD and FAAH in the colon mucosa we collected prospectively 8
colonic resection of control patients processed as previously
described [34,35]. Each blotted membrane lane was incubated
separately with the specific rabbit anti-PPARa (1:100; Fitzgerald,
cat. no. RDI-PPARAabrx), rabbit anti-NAAA (1:1000; R&D
Systems, cat. no. AF4494), rabbit anti-NAPE-PLD (1:100) and
rabbit anti-FAAH (1:100) antibodies [35], overnight at 4uC.
Western blots showed that each primary antibody detects a protein
of the expected molecular weight (see Methods S1).
Immunohistochemistry
We analyzed the distribution of PPARa, NAAA, NAPE-PLD
and FAAH in the normal colonic tissue and in the active and
quiescent UC mucosa by immunohistochemistry, following
methods previously described in Marquez et al [35]. Sections
were incubated overnight at room temperature with rabbit anti-
PPARa antibody (diluted 1:75; Fitzgerald), rabbit anti-NAAA
(diluted 1:200; R&D Systems), rabbit anti-NAPE-PLD antibody
(diluted 1:100) and rabbit anti-FAAH (diluted 1:100). Then,
sections were incubated in a biotin-conjugated donkey anti-rabbit
immunoglobulin (Amersham) diluted 1:500 for 1 hour, and
incubated in ExtrAvidin peroxidase (Sigma) diluted 1:2000 for
1 hour. We revealed immunolabeling with 0.05% diaminobenzi-
dine (DAB; Sigma), 0.05% nickel ammonium sulphate, and 0.03%
H2O2 in 0.1 M phosphate-buffered saline (pH 7.4). Sections were
dehydrated in ethanol, cleared in xylene, and coverslipped with
Eukitt mounting medium (Kindler GmbH and Co., Freiburg,
Germany).
Double immunofluorescence
Paraffin-embedded sections of colonic tissue were analyzed for
the presence of NAAA, NAPE-PLD and FAAH in plasma cells
(CD38+), B lymphocytes (CD19+), T lymphocytes (CD3+) and
macrophages (CD14+) of the lamina propria of control and UC
colitis groups. Sections were incubated overnight at room
temperature in a cocktail containing rabbit anti-NAAA, NAPE-
PLD or FAAH antibody (see above) and mouse monoclonal anti-
human CD14-IgG1 conjugated to R-phycoerythrin-Cy7
(eBioscience, San Diego, CA, USA, cat. no. 25-0149), anti-human
CD3-IgG1 conjugated to R-phycoerythrin-Cy7 (eBioscience, cat.
no. 25-0038) or conjugated to eFluorH 450 (eBioscience, cat.
Table 3. Primers sequences used for RT-PCR.
Gene symbol
(name) Oligosense (59R39) Oligoantisense (59R39)
GenBankH
accession no.
Product
size (bp)
Annealing
temperature (C6)
SP1 AGCAGGATGGTTCTGGTCAA AGGTGATGTTCCCATTCAGG NM_138473.2 210 54.0
NAPE-PLD CACGGTAATGGTGGAAATGG GTCCAGATGGTCATAGTGGTTG NM_001122838.1 178 57.0
FAAH CCCAGATGGAACATTACAGG CAGGATGACTGGTTTTCAGG NM_001441.2 187 57.6
NAAA ATGGCGCAAGTCATCGGGGA TGAAGTCACACATGCCGCGGA NM_014435.3 127 59.0
PPARa ATCACGGACACGCTTTCAC GGTCGCACTTGTCATACACC NM_001001928.2 220 58,9
PPARc TGCCATCAGGTTTGGGCGGA AATGTTTTGCCAGGGCCCGGA NM_138712.3 118 61.4
iNOS TCAGCAAGCAGCAGAATGAG ATAATGGACCCCAGGCAAGA NM_000625.4 210 63.3
doi:10.1371/journal.pone.0037729.t003
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37729Figure 1. RT-PCR (A–D), Western blot (E–H) and immunohistochemical analyses (I–T) showing the presence and distribution of
PPARa, NAAA, NAPE-PLD and FAAH in the normal human colonic tissue. Gene expressions of PPARa, NAAA, NAPE-PLD and FAAH were
detected in both mucosa (epithelium and lamina propria) and submucosa (smooth muscle and plexi) layers (A–D), and confirmed by high-
magnification photomicrographs of their protein expression by immunohistochemistry (I–T). Western blots of protein extracts from human colonic
Role of PPARa in Human Ulcerative Colitis
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37729no. 48-0038), anti-human CD19-IgG2a conjugated to R-Phyco-
erythrin (Immunostep, Salamanca, Spain, cat. no. 19PE1-100T)
or anti-human 38-IgG1 conjugated to fluorescein isothiocyanate
(Immunostep, cat. no. 38F-100T). Then, the sections were
incubated for 2 hours at room temperature in secondary donkey
anti-rabbit IgG-Cy3 antibody (dilution 1:300; Jackson Immunor-
esearch Laboratories, West Grove, PA, USA, cat. no. 711-165-
152) or goat anti-rabbit IgG-FITC antibody (dilution 1:300;
Jackson Immunoresearch Laboratories, cat. no. 111-095-003).
Quantification of mucosa immunostaining
For epithelium, we carried out a densitometrical quantification
for each protein. For lamina propria, we evaluated the type and
the number of immunostained immune cells per area (mm
2)
analyzed. In addition, quantification was segregated depending on
UC severity and treatment received: 5-ASA, glucocorticoids, and/
tissue showed prominent immunoreactive bands of the expected size for PPARa (52 kDa), NAAA (31 kDa), NAPE-PLD (46 kDa) and FAAH (62 kDa).
Positions of molecular markers (MW) are indicated at the left (E–H). Abbreviations: CSM, circular smooth muscle; E, epithelium; LSM, longitudinal
smooth muscle; LP, lamina propria; M, mucosa; MP, myenteric plexus.
doi:10.1371/journal.pone.0037729.g001
Table 4. Rating scale that summarizes the
immunohistochemical distribution in the normal human
colonic tissue (n=24)
1.
Epithelium
Lamina
propria
Smooth
muscle
Myenteric
plexus
PPARa +++ 22 ++
NAAA + +++ + 2
NAPE-PLD ++ + +++ 2
FAAH ++ + 2 ++
1Gray-scale values measured in single epithelium, lamina propria, muscular
layers and plexi are represented on an arbitrary rating scale of the
immunoreactivity of each structure. Symbols are as follows: high (+++),
moderate (++), low (+) and without immunoreactivity (2).
doi:10.1371/journal.pone.0037729.t004
Figure 2. Relative quantification of PPARa (A), PPARc (B), NAAA (C), iNOS (D), NAPE-PLD (E) and FAAH (F) gene expression in the
colonic mucosa of active UC patients compared to human healthy colonic tissue (control). Absolute values were normalized with regard to
the housekeeping gene SP1. Active UC at disease onset showed lower PPARa, PPARc and NAAA gene expression, but higher iNOS and FAAH gene
expression comparedto control. No changewas detected for NAPE-PLD gene expression. Studentt test (N=8): *P,0.05, **P,0.01 versus control group.
doi:10.1371/journal.pone.0037729.g002
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37729or immunomodulators. Digital high-resolution microphotographs
were taken under the same conditions of light and brightness/
contrast by an Olympus BX41 microscope equipped with an
Olympus DP70 digital camera and a Metal Halide epifluorescence
system (Olympus Europa GmbH, Hamburg, Germany).
Statistical analysis
Data were analyzed using SPSS 15.0 software (Statistical
Package for the Social Sciences Inc., Chicago, Illinois, USA).
Results are expressed as mean 6 S.E.M. Differences between
groups were evaluated using Student t test for parametric
observation and Mann-Whitney U and Wilcoxon tests for non
parametric observations. A P value of P,0.05 was considered
statistically significant.
Results
Presence and distribution of PPARa, NAAA, NAPE-PLD
and FAAH in the normal human colonic tissue
The normal colonic tissue showed gene expression of PPARa,
NAAA, NAPE-PLD and FAAH in the mucosa, including
epithelium and lamina propria, and the submucosa layers,
containing smooth muscle and enteric plexi (Figs. 1A–D).
Protein extracts from normal colonic tissue confirmed the
presence of protein levels of PPARa, NAAA, NAPE-PLD and
FAAH. They appeared as prominent immunoreactive bands of
expected molecular masses at ,52 kDa for PPARa, ,31 kDa
for NAAA, ,46 kDa for NAPE-PLD and ,62 kDa for FAAH
(Figs. 1E–H).
Results of the immunohistochemical distribution were summa-
rized in a rating scale (Table 4). PPARa immunoreactivity was
observed in the colonic epithelium of both absorptive and goblet
Figure 3. Representative photomicrographs and densitometrical quantification of PPARa (A–D), NAAA (E–H), NAPE-PLD (I–L) and
FAAH (M–P) immunoreactivity in human healthy (control; A, E, I, M), active UC (B, F, J, N) and quiescent UC (C, G, K, O) colonic
epithelium depending on treatment. Active UC at disease onset showed a decrease in PPARa and NAPE-PLD immunoreactivity, but an increase
in NAAA immunoreactivity. PPARa immunoreactivity showed significant differences depending on treatment. Treatment with 5-ASA in UC patients
restored completely PPARa and NAPE-PLD protein levels to control ones. However, PPARa expression dropped again in UC patients treated with 5-
ASA and glucocorticoids, and 5-ASA, glucocorticoids and immunomodulators compared to control group. In contrasts, treatment with 5-ASA and
glucocorticoids increased NAPE-PLD immunoreactivity. No changes were observed in FAAH immunoreactivity in the epithelium of control, active
(untreated) UC and quiescent (treated) UC patients. Mann-Whitney U and Wilcoxon tests (N=22–24): *P,0.05, **P,0.01, ***P,0.001 versus control
group;
#P,0.05,
##P,0.01 versus UC group;
&P,0.05 versus 5-ASA-treated quiescent UC group.
doi:10.1371/journal.pone.0037729.g003
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37729cells (Figs. 1I, J). The immunoreactivity filled the epithelial cells,
showing prominent staining in the apical and basal portions. We
did not detected PPARa immunoreactivity in immune cells of the
lamina propria, the muscularis mucosae, the muscularis externa
(circular and longitudinal smooth muscle) and the serosa (Figs. 1I,
J). Numerous PPARa-immunopositive ganglion cells were evident
only in the myenteric plexi (Figure 1K). Moderate to low intensity
of NAAA immunostaining was observed in the colonic epithelium
(Figs. 1L, M). Interestingly, we detected numerous NAAA immune
cells in the lamina propria, which showed a variety of shapes and
sizes (Fig. 1M). Muscularis mucosae, muscularis externa, plexi and
serosa showed very weak staining for NAAA (Fig. 1N). Intense
NAPE-PLD immunoreactivity was widely distributed in the
colonic epithelium, being prominent in the perinuclear portion
of the absorptive cells (Figs. 1O, P, inset). Some positive plasma
cells were also observed in the lamina propria (Fig. 1P). Strong
NAPE-PLD immunostaining defined both layers of muscularis
externa, but low immunostaining was detected in fibers of the
myenteric plexi (Fig. 1Q). FAAH immunoreactivity was mainly
detected in the colonic epithelium, which shows higher expression
in the apical portion of the epithelial cells (Figs. 1R, S). A low
number of immunoreactive immune plasma cells were observed in
the lamina propria and no staining was detected in the muscularis
mucosae, the muscularis externa and the serosa. However, we can
observe a specific FAAH immunoreactivity in nervous cells of the
myenteric plexi (Fig. 1T).
Quantification of PPARa, PPARc, NAAA, iNOS, NAPE-PLD
and FAAH gene expression in the mucosa of UC patients
In order to evaluate any changes on the expression of PPARa
signaling system in the colonic mucosa (epithelium and lamina
propria) of UC patients, we analyzed the relative differences in the
mRNA levels of selected genes such as PPARa, PPARc, NAAA,
iNOS, NAPE-PLD and FAAH in the UC mucosa, containing
epithelium and lamina propria, by quantitative RT-PCR. We
detected significantly lower levels of PPARa (P,0.05), PPARc
(P,0.01) and NAAA (P,0.05) mRNA in the mucosa of UC
patients compared to that of control ones (Figs. 2A–C). In contrast,
iNOS and FAAH gene expression was significantly higher in the
mucosa of UC patients (P,0.05) (Figs. 2D, F). We observed no
change in the levels of NAPE-PLD mRNA between both groups
(Fig. 2E).
Densitometrical quantification of PPARa, NAAA, NAPE-
PLD and FAAH immunoreactivity in the epithelium of UC
patients depending on treatment
Figure 3 shows representative microphotographs showing
qualitative differences of the immunohistochemical expression of
PPARa, NAAA, NAPE-PLD and FAAH in the colonic epithelium
of control, active and quiescent groups. Results corresponding to
the quantification of immunoreactivity are shown in Figures 3D,
H, L, P respectively. We detected a decrease of PPARa and
NAPE-PLD immunoreactivity in the epithelium of UC patients
compared to that of control ones (P,0.01 and P,0.001
respectively) (Figs. 3D, L). In contrast, NAAA immunoreactivity
was more prominent in the epithelium of active UC patients
(P,0.01) (Fig. 3H). No change was detected in FAAH immuno-
reactivity in the epithelium between active UC and control groups
(Fig. 3P). In order to address the disease severity, we analyzed the
NAE-PPARa signaling system depending on the clinical score
(mild, moderate and severe) in active UC patients (Figure S2). UC
patients with moderate clinical score showed a significant
reduction (P,0.05) of PPARa immunohistochemical expression
(Figure S2A). When NAPE-PLD immunoreactivity was analyzed,
we detected significant decreases in UC patients with mild
(P,0.01), moderate (P,0.01) and severe (P,0.001) clinical score
(Figure S2B). However, FAAH immunoreactivity was no affected
(Figure S2C). Finally, UC patients with moderate (P,0.05) and
severe (P,0.01) clinical score showed significant increases in
NAAA immunoreactivity (Figure S2D). We also analyzed the
possible effect of gender and smoking habits on the NAE-PPARa
signaling system in active UC patients. We did not detect
differences between females and males or between smokers and
non-smokers in the immunohistochemical expression in the
epithelium of active UC patients (Figures S3 and S4).
We also quantified the immunoreactivity in the colonic
epithelium of quiescent UC patients depending on the treatment
received: 5-ASA (3 cases), 5-ASA and glucocorticoids (15 cases), or
5-ASA, glucocorticoids and immunomodulators (6 cases). 5-ASA
treatment produced an increase of PPARa immunoreactivity in
the colonic epithelium of active UC patients (P,0.05), but not
when UC patients were treated with 5-ASA in combination with
other drugs (Fig. 3D). Thus, no difference in PPARa immunore-
activity was observed in UC patients treated with 5-ASA plus
glucocorticoids only or 5-ASA, glucocorticoids and immunomod-
ulators with respect untreated active UC ones. Interestingly, the
decrease in PPARa immunoreactivity observed in the epithelium
Figure 4. Estimation of acylethanolamide turnover by analyz-
ing the NAPE-PLD/NAAA (A) and NAPE-PLD/FAAH (B) ratios in
the epithelium of the untreated active and treated quiescent
UC patients in comparison with control patients. Active UC
produced a significant decrease in NAPE-PLD/NAAA and NAPE-PLD/
FAAH ratios, which were restored to control levels only after the
treatment with 5-ASA and glucocorticoids. Mann-Whitney U and
Wilcoxon tests (N=22–24): *P,0.05, ***P,0.001 versus control group;
#P,0.05 versus active UC group.
doi:10.1371/journal.pone.0037729.g004
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37729of UC patients treated with 5-ASA, glucocorticoids and immuno-
modulators was significant compared to that of UC patients
treated with 5-ASA only (P,0.05). However, we cannot detect
significant changes in NAAA immunoreactivity in the epithelium
of quiescent UC patients treated with any of the drugs, being
similar to that of active UC patients (Fig. 3H). Regarding NAPE-
PLD immunoreactive levels, there was a significant increase to
control levels in UC patients treated with 5-ASA (P,0.05) or 5-
ASA and glucocorticoids (P,0.01) compared to the active UC
patients (Fig. 3L). However, a wide variability in the intensity of
NAPE-PLD immunoreactivity was detected in UC patients treated
with 5-ASA, glucocorticoids and immunomodulators. Finally, we
cannot observe any difference in FAAH immunoreactivity in the
UC epithelium after treatment (Fig. 3P).
Acylethanolamide producing/degrading enzyme ratio in
the colonic epithelium
In order to analyze whether the differential immunohistochem-
ical expression of either acylethanolamide producing or degrading
enzymes may have resulted in an altered PPARa endogenous
ligand tone in the untreated active and treated quiescent UC
epithelium, we calculated the ratios between NAPE-PLD and
NAAA expressions, and between NAPE-PLD and FAAH expres-
sions. These ratios can suggest possible changes of OEA/PEA
levels (Fig. 4). The main result of these analysis was that there was
a significant decrease of both NAPE-PLD/NAAA (P,0.001) and
NAPE-PLD/FAAH (P,0.05) ratios in the epithelium of untreated
active UC patients. Interestingly, we detected an increase of
NAPE-PLD/NAAA and NAPE-PLD/FAAH ratios (both at
P,0.05) only in the epithelium of quiescent UC patients treated
with 5-ASA and glucocorticoids, but not with 5-ASA or 5-ASA,
glucocorticoids and immunomodulators (Fig. 4).
NAAA, NAPE-PLD and FAAH immunoreactive cells in the
lamina propria of UC patients and after treatment
The number of NAAA and FAAH immunoreactive cells in the
lamina propria showed significant changes in active UC patients
and after treatment (quiescent group). We found a significant low
number of NAAA-ir cells (2.75-fold; P,0.001) in the infiltrate of
active UC patients, but was completely restored, similar to control
level, after treatment (Fig. 5). Performing double immunofluores-
cence, NAAA expression was found in CD19-positive (+)B
Figure 5. Analysis of the number of NAAA-ir cells per area (mm
2) in the lamina propria of control group compared to acute UC
patients and after 5-ASA and corticosteroid treatment (quiescent group). A–F: Representative high-magnification photomicrographs
showing NAAA immunostaining in the lamina propria. G: Acute UC at disease onset was associated with a significant decrease in the number of
NAAA-ir cells in the infiltrate of the lamina propria. The number of NAAA-ir cells was increased to control levels after treatment (5-ASA and corticoids).
Mann-Whitney U and Wilcoxon tests (N=15–22): ***P,0.001 versus control group;
##P,0.01 versus acute UC group.
doi:10.1371/journal.pone.0037729.g005
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PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e37729Figure 6. Representative high-magnification photomicrographs showing double immunofluorescence for NAAA, CD19, CD3 and
CD14 in order to characterize the immune cells in the mucosa infiltrate of UC patients. NAAA immunofluorescence was observed in
CD19+ B lymphocytes (A–C), CD3+ T lymphocytes (D–F) and CD14+ macrophages (G–I).
doi:10.1371/journal.pone.0037729.g006
Figure 7. Analysis of the number of FAAH-ir cells per area (mm
2) in the lamina propria of acute and quiescent (5-ASA and corticoid-
treated) UC patients compared to control ones. A–F: Representative high-magnification photomicrographs showing FAAH immunostaining in
the lamina propria. G: Acute UC at disease onset was associated with a dramatic increase in the number of FAAH-ir cells in the infiltrate of the lamina
propria. The number of FAAH-ir cells was significantly dropped after treatment, but do not reach control levels. Mann-Whitney U and Wilcoxon tests
(N=15–22): ***P,0.001 versus control group;
###P,0.001 versus acute UC group.
doi:10.1371/journal.pone.0037729.g007
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(Fig. 6). In contrast, the number of FAAH-ir cells of the lamina
propria increased dramatically (10-fold; P,0.001) in active UC
patient (Fig. 7). After treatment, the number of FAAH-ir cells
decreased significantly in quiescent UC patients (P,0.001), but
did not reach control level. We did not find change in the number
of NAPE-PLD-ir cells in the lamina propria of active UC patients
and after treatment (Fig. 8). Nearly all the FAAH-ir cells in the
infiltrate expressed the plasma cell-specific CD38, which include B
lymphocytes and natural killer cells (Figs. 9A–C). NAPE-PLD
expression was mainly found in CD38+ plasma cells and CD3+ T
lymphocytes (Figs. 9 D–I).
Discussion
The key findings of this study are to demonstrate that profound
changes in the acylethanolamide-PPARa anti-inflammatory sys-
tem are produced in human UC. Overall the findings suggest that
active UC deactivate this anti-inflammatory system while 5-ASA/
glucocorticoids treatment restores its normal expression (Table 5).
The process involves both receptors and enzymes for acylethano-
lamides.
Considering PPARa receptor we found that it is mainly
expressed in the human colonic epithelium, but not in immune
cells of the lamina propria [14]. Interestingly, colonic mucosa
(epithelium and lamina propria) in active UC patients at disease
onset showed a significant down-regulation of both PPARa and
PPARc mRNA expression in colonic mucosa of active UC
patients. These data indicate that, not only PPARc, but also
PPARa, are implicated in the pathophysiology of the human
colonic inflammation. We also detected an over-expression of
iNOS mRNA, a pro-inflammatory mediator that produces nitric
oxide species and leads oxidative stress and cell death [11,36,37].
This enzyme is under the active control of PPARa receptor since
PPARa agonists enhance its degradation [38]. Immunohisto-
chemical results demonstrated that PPARa mRNA down-expres-
sion in the UC mucosa correlated with PPARa protein down-
expression in the UC epithelium. Moreover, only 5-ASA
treatment increased immunohistochemical expression of PPARa
to control expression level, but not when UC patients were treated
with 5-ASA in combination with glucocorticoids and/or immu-
nomodulators.
5-ASA is structurally related to nonsteroidal anti-inflammatory
drugs that shares molecular targets including inflammation,
proliferation and/or apoptosis [39–41]. 5-ASA inhibits inflamma-
tion by scavenging free radicals and thus interfering with the
arachidonic acid metabolism [42]. Recent studies indicated that
the anti-inflammatory effect of 5-ASA is mediated by the
activation of PPARc [9–11], a nuclear receptor whose agonists
can suppress or delay inflammation effectively by inhibiting
multiple steps in NF-kB and AP-1 signaling pathways [7,8] and
attenuating the production of nitric oxide (iNOS) and macro-
phage-derived cytokines such as TNFa, IL-1 and IL-6 in mouse
models of colitis [16,43,44]. Moreover, Linard et al. [11] showed
that 5-ASA is able to induce PPARa, PPARc and RXRa co-
expression and promote their translocation to the nucleus in an
animal model of irradiation-induced intestinal inflammation. In
the present study, we demonstrated that 5-ASA specifically
increased the expression of PPARa in the human UC epithelium
suggesting that, not only PPARc, but also PPARa can be a key
receptor for the potent anti-inflammatory effect of 5-ASA in the
human UC [9,10]. At this time, nothing at all is known about the
regulation of PPARa expression and much more studies are
needed to elucidate the anti-inflammatory mechanisms of 5-ASA.
Others components of the PPARa signaling system, such as
NAPE-PLD, FAAH and NAAA, are expressed in the healthy
colonic epithelium and immune cells of the colonic lamina propria
in humans [35]. NAPE-PLD is one of several N-acylethanolamide-
biosynthesis enzymes that catalyze the release of N-acylethanola-
mide (NAE) from N-acyl-phosphatidylethanolamine (NAPE),
converting endogenous lipids into chemical signals like oleoyletha-
nolamine (OEA), palmitoylethanolamine (PEA) and anandamide
(AEA) [41,42,45,46]. Some studies showed that the biological
activity of PEA, such as anti-inflammatory and analgesic activities
[47], and OEA, such as food intake [48–50], are mediated by non-
cannabinoid receptors among which PPARa is probably the most
important [51–53]. In mammalian tissues, three enzymes respon-
sible for hydrolyses of NAEs to fatty acids and ethanolamine have
been identified: FAAH-1, FAAH-2 (human isozyme) and NAAA
[24,54–57]. Thus, it has been shown that selective FAAH or
NAAA inhibitors produced an anti-inflammatory effect [26–29].
Interestingly, FAAH and NAAA have different catalytic properties
and substrate specificity [24]. FAAH is catalytically active at
neutral and alkaline pH and shows the highest reactivity with
anandamide, followed by OEA and PEA [58]. In contrast, NAAA
activity is optimum at pH 4.5–5, being inactive at alkaline pH,
and hydrolyzes PEA much faster than others NAEs [24,55].
Therefore, alterations of FAAH and NAAA activity can be as a
result of variations of luminal pH in colonic inflammation, and it is
Figure 8. Analysis of the number of NAPE-PLD-ir cells per area
(mm
2) in the lamina propria of acute and quiescent (5-ASA and
corticoid-treated) UC patients compared to control ones. A–D:
Representative high-magnification photomicrographs showing NAPE-
PLD immunostaining in the lamina propria. E: No significant change in
the number of NAPE-PLD-ir cells was observed in the infiltrate of the
lamina propria of acute UC patients and after treatment (5-ASA and
corticoids). Mann-Whitney U and Wilcoxon tests (N=15–22).
doi:10.1371/journal.pone.0037729.g008
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anti-inflammatory effects of PPAR endogenous agonists [59].
In the present study, we demonstrated that mRNA and protein
expression of NAPE-PLD, FAAH and NAAA was partially altered
in active colitis, and immunohistochemical expression of these
enzymes was partially restored after treatment (quiescent colitis) in
a tissue-dependent manner (epithelium and immune cells of the
lamina propria). Overall, the present data suggested that both
increase of NAAA expression and lack of change in FAAH
expression in the UC epithelium agree with a substantial reduction
of luminal pH in the colon of UC patients [59]. Therefore, NAPE-
PLD down-expression and NAAA over-expression in UC epithe-
lium might let to a net reduction in NAEs turnover (specifically
PEA) in the epithelium, leading the attenuation of the anti-
inflammatory response via the activation of PPAR receptors
(Fig. 10). Interestingly, inflammation associated with osteoarthritis
and rheumatoid arthritis showed a lower concentration of PEA in
the synovial fluid compared to non-inflamed normal volunteers
[60]. Changes observed in NAPE-PLD, FAAH and NAAA
mRNA expression in the mucosa (epithelium and lamina propria)
correlated completely with changes observed in the number of
immunoreactive cells in the lamina propria of UC patients, but not
with their immunohistochemical expression in the UC epithelium
(see Table 5). These discrepancies can be explained by a higher
expression of these enzymes in the immune cells during UC
Figure 9. Representative high-magnification photomicrographs showing double immunofluorescence for FAAH, NAPE-PLD, CD38
and CD3 in order to characterize the immune cells in the mucosa infiltrate of UC patients. Nearly all FAAH immunofluorescent cells are
plasma cell-specific CD38 (A–C). NAPE-PLD immunofluorescence was observed in both CD38+ plasma cells (D–F) and CD3+ T lymphocytes (G–I).
doi:10.1371/journal.pone.0037729.g009
Table 5. Summary of the changes detected in PPARa signaling system (PPARa, NAPE-PLD, FAAH and NAAA) in the colonic
epithelium and lamina propria of active UC patients and after treatment (quiescent UC patients)
1.
Gene expression Immunohistochemical expression in epithelium
Number of immunoreactive cells in lamina
propria
Active untreated-UC Active untreated-UC Quiescent treated-UC Active untreated-UC Quiescent treated-UC
PPARa Q (*) Q (**) q (*) (5-ASA) nc nc
NAPE-PLD nc Q (***) q (**) (5-ASA+ glucocortic.) nc nc
FAAH q (*) nc nc q (***) Q (***)
NAAA Q (*) q (**) nc Q (***) q (**)
1Symbols are as follows: increased expression (q), decreased expression (Q), no change (nc). Statistical significance was represented by.
*P,0.05,
**P,0.01 and
***P,0.001.
doi:10.1371/journal.pone.0037729.t005
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signaling system in colonic epithelium and lamina propria.
In the lamina propria of healthy human colon, we found that
the number of NAAA-ir immune cells was 50-fold higher than the
number of FAAH-ir immune cells. These data can suggest a
higher rate of PEA hydrolysis in comparison with AEA hydrolysis.
In the lamina propria of active UC, we found that the number of
FAAH-ir immune cells increased up to 10-fold, whereas the
number of NAAA-ir immune cells decreased up to 2.75-fold,
suggesting a concomitant increase of AEA hydrolysis as well as
decrease of PEA hydrolysis. These results can be related with the
fact that AEA activates cannabinoid (CB1 and CB2) receptors,
whereas PEA is inactive on these receptors, but activates PPARa
[51], playing different roles in inflammatory activation. Previous
biochemical and immunochemical analysis demonstrated NAAA
expression in macrophage cells of the rat lung and brain [25].
Here, we showed that NAAA is predominantly expressed in
macrophages and B and T lymphocytes in the lamina propria of
UC patients. Most FAAH-ir cells in the lamina propria of UC
patients expressed CD38, a surface glycoprotein found in plasma
B and natural killer cells, and this result agrees with previous
studies showing FAAH activity in lymphocytes [61]. NAPE-PLD-
ir cells in the lamina propria of UC patients were CD38+ plasma
cells and CD3+ T lymphocytes, but not CD14+ macrophages,
contrary to expectation after pro-inflammatory stimuli [62].
UC-specific treatments produced tissue-dependent impairments
in the expression of PPARa signaling system. NAPE-PLD, but not
NAAA or FAAH, responded to treatment in the epithelium, while
NAAA and FAAH, but not NAPE-PLD, responded to treatment
in the immune cells of the lamina propria of UC patients. 5-ASA
produced an increase of NAPE-PLD immunohistochemical
expression (similar to control levels) in the quiescent UC
epithelium, which was enhanced after corticosteroid treatment.
Interestingly, the analysis of the NAPE-PLD/NAAA and NAPE-
PLD/FAAH ratios suggested an increase of NAEs production in
the UC epithelium after 5-ASA/corticosteroid treatment, but not
when patients were treated exclusively with 5-ASA. It is clear that
5-ASA treatment leads to an increase of NAPE-PLD and PPARa
expression, so probably both 5-ASA and the concomitant over-
production of NAEs via glucocorticoids can enhance an anti-
inflammatory response in the epithelium of UC patients by the
activation of PPARa (Fig. 10). This hypothesis agrees with
previous data indicating that glucocorticoids generate anti-
inflammatory regulatory responses by promoting arachidonic
acid-containing lipid biosynthesis [63]. Treatment also increases
the number of NAAA-ir immune cells, reaching control levels and,
probably, normalizing PEA hydrolysis. However, the significant
decrease of FAAH-ir immune cells after treatment did not reach
control levels, so there may be still an over-degradation of AEA in
the lamina propria of UC patients.
We must pay attention on two limitations related with the
cohort of patients used in the present study. As a result of
prioritizing clinical, endoscopical and histopathological consider-
ations to obtain a homogeneous cohort, control and UC groups
were not-age matched. Additionally, smoker patients and patients
and controls from both genders were included in the study.
However, these factors cannot be included in additional analysis
because of the size of the cohort, designed to be a within-subject
design (patients were they own control for quiescence status).
In conclusion, our results indicated that PPARa, NAPE-PLD,
FAAH and NAAA form part of a key lipid signaling system that
regulates UC-activated inflammatory response in human. 5-ASA,
through PPARa receptor, and glucocorticoids, through acylethe-
nolamide producing/degrading enzymes, reduces colitis-associat-
ed inflammation suggesting PPARa agonists or FAAH/NAAA
inhibitors as potential drugs for the treatment of inflammatory
bowel diseases in human.
Supporting Information
Figure S1 Housekeeping gene expressions of SP1 tran-
scription factor (A) and bACTIN (B) represented by the
threshold cycles (C(t)). We cannot detect differences in gene
expression between control and active UC patients. Student t-test
Figure 10. Schematic drawings that hypothesize the normal
pattern of NAE-PPARa activity (A), and the pro- and anti-
inflammatory NAE-PPARa signaling that may occur in the
colonic epithelial cells of active UC at disease onset (B) and
after a putative treatment with 5-ASA and/or glucocorticoids
(C).
doi:10.1371/journal.pone.0037729.g010
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P=0.597).
(TIF)
Figure S2 Densitometrical quantification of PPARa (A),
NAPE-PLD (B), FAAH (C) and NAAA (D) immunoreactiv-
ity in human healthy (control) and active UC colonic
epithelium depending on severity (mild, moderate and
severe). Mann-Whitney U and Wilcoxon tests (N=22–24):
*P,0.05, **P,0.01, ***P,0.001 versus control group.
(TIF)
Figure S3 Densitometrical quantification of PPARa (A),
NAPE-PLD (B), FAAH (C) and NAAA (D) immunoreactiv-
ity in active UC colonic epithelium depending on gender.
No statistical difference was observed. Student t-test (N=22–24).
(TIF)
Figure S4 Densitometrical quantification of PPARa (A),
NAPE-PLD (B), FAAH (C) and NAAA (D) immunoreactiv-
ity in active UC colonic epithelium depending on
smoking habits. No statistical difference was observed. Student
t-test (N=22–24).
(TIF)
Methods S1 mRNA isolation and quantitative RT-PCR
analysis.
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